http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 06:43:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29/26650114.html <p>H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $95.00 price target on Halozyme Therapeutics (NASDAQ: HALO).</p><p>The analyst commented: "CMS’ IPAY 2029 proposal leaves multiple routes for major royalty products to avoid MFP exposure, while ENHANZE demand seems strong. Under the proposed rule, CMS would no longer treat an ENHANZE-enabled subcutaneous (SC) formulation as a separately protected product simply because hyaluronidase enables an alternative route of administration. Instead, where the same BLA holder is involved, CMS would aggregate the SC and intravenous (IV) versions under the same shared active ingredient. While investors had worried that this could devalue ENHANZE, http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29/26650114.html Tue, 16 Jun 2026 06:43:54 -0400 HALO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+12++Filed+by%3A+Snyder+Mark+Howard/26647409.html si-local-file:///var/storage/secattach/20260615/26647409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+12++Filed+by%3A+Snyder+Mark+Howard/26647409.html Mon, 15 Jun 2026 16:10:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+12++Filed+by%3A+Snyder+Mark+Howard/26647409.html si-local-file:///var/storage/secattach/20260615/26647409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+12++Filed+by%3A+Snyder+Mark+Howard/26647409.html Mon, 15 Jun 2026 16:10:00 -0400 HALO O.00978404 http://www.streetinsider.com/Corporate+News/Halozyme+expects+minimal+Medicare+pricing+impact+on+royalties+through+2035/26643498.html <p>Halozyme Therapeutics Inc. (NASDAQ: HALO) said it projects zero to minimal impact on royalty revenue through at least 2035 following its analysis of a proposed Medicare Drug Price Negotiation Program rule released by the U.S. Centers for Medicare & Medicaid Services on June 12.</p><p>The San Diego-based biopharmaceutical company said the projection is based on the proposed rule for the program's implementation period starting in 2029. Chief Executive Officer Helen Torley said the company also expects no impact on its ability to execute new ENHANZE partnership agreements.</p><p>"Based on our analysis of CMS's proposed rule and the statutory framework established under the http://www.streetinsider.com/Corporate+News/Halozyme+expects+minimal+Medicare+pricing+impact+on+royalties+through+2035/26643498.html Mon, 15 Jun 2026 06:01:14 -0400 HALO http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/Press+Releases/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the <span>U.S. Centers for Medicare &amp; Medicaid Services</span> ("CMS") on <chron>June 12, 2026</chron>.</p><p class="prntaj">"Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), <span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span> projects zero to minimal impact to its http://www.streetinsider.com/PRNewswire/Halozyme+Confirms+It+Projects+Zero+to+Minimal+Impact+to+Royalty+Revenue+Through+At+Least+2035+Based+on+Newly+Released+Draft+Medicare+Drug+Price+Negotiation+Program+Proposed+Rule+for+IPAY+2029/26643465.html Mon, 15 Jun 2026 06:00:00 -0400 A.30035300 HALO O.00978404 O.20947283 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+08++Filed+by%3A+Snellgrove+Darren/26624535.html si-local-file:///var/storage/secattach/20260609/26624535.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+08++Filed+by%3A+Snellgrove+Darren/26624535.html Tue, 09 Jun 2026 16:59:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+08++Filed+by%3A+Snellgrove+Darren/26624535.html si-local-file:///var/storage/secattach/20260609/26624535.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+08++Filed+by%3A+Snellgrove+Darren/26624535.html Tue, 09 Jun 2026 16:59:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Torley+Helen/26601034.html si-local-file:///var/storage/secattach/20260603/26601034.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Torley+Helen/26601034.html Wed, 03 Jun 2026 20:07:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Torley+Helen/26601034.html si-local-file:///var/storage/secattach/20260603/26601034.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Torley+Helen/26601034.html Wed, 03 Jun 2026 20:07:00 -0400 HALO O.00978404 http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29+on+Near-Term+Potential/26596497.html <p>Benchmark analyst Robert Wasserman reiterated a Buy rating and $90.00 price target on Halozyme Therapeutics (NASDAQ: HALO).</p><p>The analyst commented, "We believe much of the recent investor angst over HALO appears to be focused on longer-term issues, for example the potential effect of the impact of the 2022 Inflation Reduction Act (IRA) and the subsequent CMS Drug Negotiation program as well as the ongoing patent litigation with Merck over their recently launched subcutaneous Keytruda product. Nearer-term issues such as integration of recent acquisitions, the impact of rising costs, scrip trends of partnered products, or clinical progress of earlierstage partnered products, seem http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29+on+Near-Term+Potential/26596497.html Wed, 03 Jun 2026 09:02:08 -0400 HALO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Connaughton+Bernadette/26593277.html si-local-file:///var/storage/secattach/20260602/26593277.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Connaughton+Bernadette/26593277.html Tue, 02 Jun 2026 17:20:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Connaughton+Bernadette/26593277.html si-local-file:///var/storage/secattach/20260602/26593277.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Jun+01++Filed+by%3A+Connaughton+Bernadette/26593277.html Tue, 02 Jun 2026 17:20:00 -0400 HALO O.00978404 http://www.streetinsider.com/New+Coverage/JPMorgan+Reinstates+Halozyme+Therapeutics+%28HALO%29+at+Neutral/26523868.html <p>JPMorgan analyst Jessica Fye reinstates coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Neutral rating and a price target of $70.00.</p> <p>For an analyst ratings summary and ratings history on Halozyme Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=HALO">click here</a>. For more ratings news on Halozyme Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=HALO&amp;type=analyst">click here</a>.</p> <p>Shares of Halozyme Therapeutics closed at $68.73 yesterday.</p> http://www.streetinsider.com/New+Coverage/JPMorgan+Reinstates+Halozyme+Therapeutics+%28HALO%29+at+Neutral/26523868.html Wed, 20 May 2026 04:31:03 -0400 HALO http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+LaBrosse+Nicole/26505662.html si-local-file:///var/storage/secattach/20260515/26505662.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+LaBrosse+Nicole/26505662.html Fri, 15 May 2026 16:18:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+LaBrosse+Nicole/26505662.html si-local-file:///var/storage/secattach/20260515/26505662.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+LaBrosse+Nicole/26505662.html Fri, 15 May 2026 16:18:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+May+11++Filed+by%3A+Torley+Helen/26487766.html si-local-file:///var/storage/secattach/20260513/26487766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+May+11++Filed+by%3A+Torley+Helen/26487766.html Wed, 13 May 2026 17:50:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+May+11++Filed+by%3A+Torley+Helen/26487766.html si-local-file:///var/storage/secattach/20260513/26487766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+May+11++Filed+by%3A+Torley+Helen/26487766.html Wed, 13 May 2026 17:50:00 -0400 HALO O.00978404 http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+MRAM+HALO+DGXX+DT+SGI+CM+KOPN+/26480694.html <p>Increasing unusual call option volume: MRAM HALO DGXX DT SGI CM KOPN</p> http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+MRAM+HALO+DGXX+DT+SGI+CM+KOPN+/26480694.html Wed, 13 May 2026 05:40:22 -0400 HALO